H.A. Chaudri

Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.

P Dombernowsky, I E Smith, Geoffrey Falkson et al. · Journal of Clinical Oncology · 1998 · 640 citations

Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer

M. Gershanovich, H.A. Chaudri, Diogo Ayres‐de‐Campos et al. · Annals of Oncology · 1998 · 263 citations · Full text

Advanced Breast Cancer, Breast Oncology, Oncology +11

Report on a Long-Term Tolerability Study of Up to Two Years with Diclofenac Sodium (Voltaren)

S N Ciccolunghi, H.A. Chaudri, B I Schubiger et al. · Scandinavian Journal of Rheumatology · 1978 · 45 citations

Electrolyte Disorder, Pharmacotherapy, Orthopaedic Surgery +22

Clinical use of aromatase inhibitors in the treatment of advanced breast cancer

Patrick Trunet, Franzanne Vreeland, Catherine Royce et al. · The Journal of Steroid Biochemistry and Molecular Biology · 1997 · 21 citations

Advanced Breast Cancer, Breast Oncology, Oncology +10

Interleukin-6 induction by a muramyltripeptide derivative in cancer patients.

Heiner Frost, James L. Murray, H.A. Chaudri et al. · PubMed · 1990 · 19 citations

Inflammation, Cytokine, Autoimmune Disease +14